Wed 31-08-2022 23:12 PM
WASHINGTON, Aug. 31, 2022 (WAM) — Today, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorizations (EUAs) for the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine to provide bivalent approved the formulation. Amount of vaccine to be used as a single booster dose at least 2 months after primary or booster vaccination.
A bivalent vaccine, also called an ‘updated booster’, contains two messenger RNA (mRNA) components of the SARS-CoV-2 virus. The BA.4 and BA.5 lineages of the Omicron variant of SARS-CoV-2, FDA said in a statement.
Moderna COVID-19 vaccine, Vivalent, is licensed for use as a single booster dose in individuals 18 years of age and older. The Pfizer-BioNTech COVID-19 vaccine, Bivalent, is licensed for use as a single booster dose in individuals 12 years of age and older.
The monovalent COVID-19 vaccine that has been approved or approved by the FDA and administered to millions of people in the United States since December 2020 contains components of the original strain of SARS-CoV-2. I’m here.
Wam/Hatem Mohamed/Tariq Alfaham